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Supplemental Discussion 
During apoptosis, and coincident with MOMP, mitochondria undergo a dramatic change 
in dynamics, resulting in mitochondrial fragmentation (Frank, et al., 2001).  It was 
therefore conceivable that the loss of mitochondrial mass we observed (Figure 6) was a 
direct consequence of this fragmentation event. However, measurements of 
mitochondrial mass before and shortly after MOMP in single cells failed to show any 
significant loss of total mitochondrial mass, despite extensive mitochondrial 
fragmentation (data not shown).  Based on this and the above observations, we suggest 
that the loss of mitochondrial mass we observed is a consequence of autophagy. 
 
In contrast to the effects of GAPDH in recovery from MOMP in proliferating cells, 
GAPDH has been reported to trigger a caspase-independent cell death in neurons (Berry 
and Boulton, 2000; Sirover, 1999).  Intriguingly, neurons are capable of recovering from 
MOMP provided caspases are not activated (Martinou et al., 1999) and mitochondria 
sustain ∆Ψm (Deshmukh et al., 2000).  This effect is only observed in neurons deprived 
of neurotrophic factors and occurs upon restoration of the factor; other inducers of   2
MOMP and apoptosis, such as those we have employed in our studies, induce MOMP 
from which the neuronal cells cannot recover (Deshmukh et al., 2000). 
 
Studies have explored ways in which the glycolytic pathway contribute to cellular 
survival upstream of MOMP (Majewski et al, 2004; Vander Heiden et al., 2001).  Our 
results suggest that the metabolic dynamics of the cell, and the process of autophagy, can 
provide protection even following this proposed “point of no return,” through the 
engagement of cellular and organellar repair processes that appear to involve both 
cytosolic and nuclear functions of GAPDH in elevating ATP levels and promoting 
autophagic removal of damaged mitochondria. 
 
Supplemental Experimental Procedures 
Cloning and retroviral transduction 
GAPDH (EC1.2.1.12, accession number: M33197) was cloned by standard PCR based 
strategies from a Jurkat cDNA library using the following oligonucleotides (sense 
containing an EcoRI site 5'-AGAATTCAAAATGGGGAAGGTGAAGGTCGGA-3' and 
antisense containing BamHI site and the sequence corresponding to the V5 tag 5'-
CGGGATCCCGAAATCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAG
GCTTACCCTCCTTGGAGGCCATGTGGGC-3' into the donor vector pDNR-1R (BD 
Bioscience Clontech) and then subcloned to the retroviral vector pLP-LNCX (BD 
Bioscience Clontech) following the manufacturer's instructions. Recloning of GAPDH in 
this way was done to ensure that the effects we observed were indeed due to this gene 
rather than some other effect.  The deletion mutants (V5 tagged) were generated by PCR   3
and subcloned into the retroviral vector pLPCX (BD Bioscience Clontech) using the 
following oligonucleotides: for the fragments corresponding to amino acids 1-150 and 1-
261, sense containing a BglII site: 5’-GAAGATCTTACCATGGGGAAGGTGAAGG-3’ 
and antisense containing an EcoRI site: 5’-GGAATTCCTTACGTAGAATCGAGACCG 
AGGAGAGGGTTAGGGATAGGCTTACCGGCATTGCTC-3’ and 5’-GGAATTCCTT 
ACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCACCTTCTT
G-3’, respectively; for the fragment corresponding to amino acids 150-336, sense 
containing a BglII site: 5’-GAAGATCTTACCATGGCCTCCTGCACCACCAAC-3’ and 
antisense containing a EcoRI site: 5’-GGAATTCCTTACGTAGAATCGAGACCGAGG 
AGAGGGTTAGGGATAGGCTTACCCTCCTTGGAG-3’. Single mutations were 
introduced using QuikChange Site-Directed Mutagenesis Kit (Stratagene) with the 
following oligonucleotides. To replace Cys149 by Ser: sense oligo 5’-
GCAATGCCTCCTCCACCACCAACTGCTTAGC-3’ and anti-sense oligo 5’-
GCTAAGCAGTTGGTGGTGGAGGAGGCATTGC-3’; to replace His176 by Phe: sense 
oligo 5’-GGACTCATGACCACAGTCTTTGCCATCACTGCCACCC-3’ and anti-sense 
oligo 5’-GGGTGGCAGTGATGGCAAAGACTGTGGTCATGAGTCC-3’. After cloning 
and mutation, each construct was verified by sequencing. 
 
Atg12 (accession number: NM 004707) was cloned by standard PCR based strategies 
from a HeLa cDNA library using the following oligonucleotides: sense  5’-
CGATTTGAATGACTAGCCGGGAAC-3' and antisense: 5’-TCCCCACGCCTGAGAC 
TTGCAGTAATG-3' and then subcloned into a pcDNA3.1/V5-His TOPO vector. After 
cloning the construct was 100% sequenced and no mutation was identified.   4
 
Oncogene transduction 
Apaf-1-deficient mice were obtained from Dr. Tak Mak (U. Toronto) and Dr. Xiaodong 
Wang (UT Southwestern).   Mouse embryonic fibroblasts (MEFs) were prepared from 
day 13.5 embryos.  The head and the red organs were removed and the torso minced and 
dispersed in 0.1% trypsin (45 min at 37ºC).  The wild-type MEFs used for comparison 
were derived from the same crosses.  MEFs were maintained in DMEM plus 10% FBS 
and used between passages 2 and 5. 
 
Early-passage MEF were simultaneously transduced with frozen supernatants of the 
appropriate retroviral expression vectors. The plasmids pBabePuro.H-ras (G12V) and 
pWZLH.E1A were provided by S.W. Lowe and G. Hannon. The plasmids containing the 
wt GAPDH and their mutated forms were generated as described above. After 48 hrs, the 
cells were harvested by mild trypsination, seeded at 5x10
4cells/well in 6 well plates and 
cultured for 10 days in media containing 1 µg/ml of puromycin, 50 µg/ml of hygromycin 
or 1 mg/ml of G418 for selection of the transduced viruses. For loci enumeration, cells 
were washed with PBS, fixed with 70% ethanol for 1h and stained with methylene blue 
(0.1% in methanol). Successful transduction was confirmed in parallel experiments using 
a GFP-expressing retroviral vector.   
 
Cell viability, proliferation, and cell death   5
In addition to clonogenic assays, assessment of plasma membrane integrity was analyzed 
as follows.  Cells were trypsinized and labelled with trypan blue for visual assessment, or 
propidium iodide (PI; 1 µg/ml) at 37°C, followed by cytofluorometric analysis. 
 
Cell division was examined by carboxyfluorescein diacetate succinimidyl ester (CFSE) 
(Molecular Probes) dye dilution analysis, as described (Lyons, 2000). 10
6cells/ml were 
resuspended in PBS containing 0.1% BSA with a final CFSE concentration of 5 µM, mix 
gently and incubated for 10 min at 37
oC. The labeling tubes were immediately filled with 
culture media with 10% FBS to block the reaction. The cells were washed three times 
with culture media prior to seed. CFSE fluorescence was analyzed at indicated times by 
flow cytometry collecting the fluorescence intensity of the individual cells in FL1. 
 
In some cases, prior to cell death induction cells were incubated with the autophagy 
inhibitors bafilomycin A1 (Baf A1; 0.1 µM; Sigma) or 3-methyladenine (3-MA; 10 mM; 
Sigma) for 6 hrs (and during the additional 6 hrs of treatment with cytotoxic agents).  
Alternatively, cells were treated with the antioxidants mitoQ (1 µM; Kelso et al., 2001), 
butylated hydroxyanisole (BHA; 200 µM; Sigma) and N-acetyl-cysteine (NAC; 10 mM; 
Sigma) for 1 hr prior to treatment with cytotoxic agents.   Following cell death induction 
for an additional 6 hrs, antioxidants were readded to the cultures.  
 
Jurkat cells were grown in RPMI with low (0.3 mM, plus 5 mM sodium pyruvate ) or 
high (4 mM) glucose for at least 2 weeks prior to the experiment.   6 well plates were 
coated over night with anti-CD3 (10 µg; Clone X3, a gift from Prof. A Bernard, Inserm,   6
Nice), and 10
6 Jurkat cells/ well were activated for 24hrs. The following day the cells 
were treated with Act D (0.5 µM for 6 hrs) ± qVD-oph (20 µM), then washed and 
distributed in a 96 well plate (±qVD-oph). 24 hrs later, the number of cells present in 
each well was determined by visual inspection. 7 days later the number of wells 
containing growing clones was assessed.  The results represent an average ± S.D. of 3 
independent experiments and correspond to the number of cells able to form a colony 
after 8 days (in %).  
 
Measurement of GAPDH activity 
GAPDH activity was analyzed using a fluorescence-based assay kit (KDalert
TM GAPDH, 
Ambion) following the manufacturer’s instructions. In brief, 10
4 cells were resuspended 
in 200 µl lysis buffer and incubated on ice for 20 min. 10 µl aliquots from each sample 
were transferred to a 96 well microplate and 90 µl of the master mix was added. The 
increase in fluorescence over 4 min was integrated using a fluorescence plate reader. The 
GAPDH activity of the samples was determined by comparing values to a standard curve 
for GAPDH enzyme and corrected for measured cell protein. 
 
Measurement of cellular ATP 
ATP assays were performed using the ATP Bioluminescence assay kit HSII (Roche) 
following the manufacturer’s instructions.  In brief, 10
5 cells were washed once with ice-
cold PBS, collected by centrifugation at 800xg and resuspended in 100 µl lysis buffer. 
Aliquots from each sample were diluted to 100 µl in dilution buffer, 100 µl of luciferase 
reagent added and the luminescence integrated over 10 s using a Monolight 2010   7
luminescence recorder (Analytical Luminescence Laboratory).  The ATP levels of the 
samples were determined by comparing values to a standard curve for ATP performed at 
the same time.  In some cases, ATP values were confirmed by HPLC using a reverse-
phase Nucleosil column (C18, 5µm particle size, 25 x 0.4 cm; Teknokroma, San Cugat, 
Spain) coupled to a 600 HPLC system equipped with a Waters 996 photodiode array 
detector. Absorbance was monitored at 260 nm. Nucleotide separation was allowed to 
proceed in a isocratic fashion with 200 mM  potassium phosphate (pH 5.8) as described 
(Jones, 1981). 
 
Measurement of ROS  
Production of ROS was monitored spectrofluorimetrically by using the fluorescent probe 
2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA; 1 µM; Molecular Probes). Cells 
were incubated with the dye for 1 hr, followed by washing and determination of 
fluorescence at 529 nm/503 nm (emission/excitation). Levels of ROS were corrected for 
background fluorescence associated
 with reagents and inhibitors. 
 
Immunoblotting  
Cells were lysed in RIPA buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
0.1% SDS, 1% Triton x-100, 1% sodium deoxycholate with protease inhibitors 
(Complete Cocktail, Boehringer Mannheim).  Lysates were standardized for protein 
content and resolved by SDS-PAGE.  The proteins were transferred to supported Hybond 
C nitrocellulose (Amersham Bioscience) and immunodetected using anti-GAPDH 
(Chemicon; 1:1,000), anti-V5 (Invitrogen; 1:5,000) anti-actin (clone C4, ICN   8
Pharmaceuticals; 1:1,000) anti-p53 (clone Do7, BD Pharmingen; 1:1,000) anti-
p21/WAF1 (clone SX118, BD Pharmingen; 1:1,000) anti-atg12 (Zymed Laboratories; 
1:500), anti-Beclin (Novus Biological Inc; 1:1,000) or anti-hsp60 (clone LK-1, Stressgen; 
1:1,000) antibodies followed by the appropriate peroxidase-coupled secondary antibodies 
(Amersham Bioscience). Proteins were then visualized by enhanced chemiluminescence 
(ECL, Amersham Bioscience).  Quantification of immunoblots was performed using NIH 
image. 
 
Immunocytochemistry and confocal microscopy 
For immunocytochemistry cells were grown on glass coverslips, rinsed once with PBS 
and fixed for 10 min with 4% paraformaldehyde in 0.1 M phosphate buffer prior to 
permeabilization with 0.1% saponin in blocking buffer (1% BSA in PBS) for 15 min. 
Cells were then incubated in presence of anti-GAPDH (Chemicon) diluted 1:200 in 
blocking buffer with 0.025% saponin for 1 hr at RT.  Excess antibody binding was 
removed by washing the coverslips three times with PBS.  The secondary antibody, 
Texas Red-conjugated anti-mouse Ig (Amersham Bioscience), diluted 1:200 in blocking 
buffer was added and incubated  for 1 hr at RT.  After three washes with PBS, the 
coverslips were mounted onto microscope slides using Fluoromount-G reagent (Southern 
Biotech). Fluorescence was monitored in a Nikon Eclipse TE 300 microscope with a Bio-
Rad MRC 1024 confocal laser unit, using a 543 nm line from a helium neon laser 
attenuated at 85%.  Data from two Kalman-averaged scans were obtained using 
LaserSharp 2000 software (Bio-Rad). 
   9
For analysis of the mitochondrial cytochrome c recovery, HeLa cytochrome c-GFP cells 
(Goldstein et al., 2000) were seeded individually in 3 mm wells generated using press-to-
seal silicone isolators (Grace Bio-Labs) secured to the bottom of Lab-Tek chamber slides 
(Nalge Nunc International).  The GFP fluorescence was monitored by confocal 
microscopy using a 488 nm line from an Ar/Kr laser attenuated at 90% and detected after 
transmission of a 522DF35 bandpass filter. 
 
Measurement of cytochrome c release and loss of ∆Ψm by flow cytometry 
To analyze mitochondrial cytochrome-c-GFP release, trypsinized cells were resuspended 
in 100 µl ice-cold cell-lysis and mitochondria intact (CLAMI) buffer (250 mM sucrose, 
80 mM KCl, 50 µg ml
-1 digitonin in PBS) and incubated on ice for 5-10 min.  Aliquots 
from the suspensions were stained with 0.1% trypan blue in PBS to ensure that 100% of 
the cells were permeabilized.  Then, 200 µl of digitonin-free CLAMI buffer was added to 
each sample and analyzed immediately by flow cytometry on a Becton Dickinson 
FACSCalibur, collecting the fluorescence intensity of the GFP of the individual cells in 
FL1 (Waterhouse and Trapani, 2003). 
 
The mitochondrial membrane potential was measured using tetramethylrhodamine ethyl 
ester (TMRE; Molecular Probes) (Scaduto and Grotyohann, 1999). 10
6 cells/ml were 
incubated at 37ºC for 20 min in media containing 50 nM TMRE and the dye retention 
was analyzed by flow cytometry.  As a positive control for ∆Ψm loss, cells were 
incubated at the same time with the uncoupling agent carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone (FCCP, 10 µM; Sigma), a protonophore which   10
disrupts  ∆Ψm.  At least 10,000 events were collected per sample, with the TMRE 
fluorescence recorded as logarithmic amplified data in FL2. 
 
For determination of mitochondrial mass, fluorescencent probe 10-n-nonyl acridine 
orange (NAO, 10 µM; Molecular Probes), which is accumulated in mitochondria 
regardless of ∆Ψm, was added to the culture media and incubated for 15 min at 37ºC. 
Cells were then trypsinized and resuspended in PBS. The NAO fluorescence was 
analyzed by flow cytometry. 
Microarray  
The oligonucleotide microarrays contained ~25,000 distinct oligonucleotide probes 
covering most of the known human transcripts. The list of the probes (median length 
~51pb) is available on line (http://www.microarray.fr). RNAs were labelled using an 
amplification protocol, as described (Le Brigand et al., 2006). Briefly, 1 µg of total RNA 
was amplified with the Amino Allyl MessageAmp aRNA kit (Ambion, 2130 Woodward, 
Austin TX) according to manufacturer’s instructions. Cy3 and Cy5 labelled aRNA was 
fragmented with the Ambion aRNA Fragmentation Reagents, purified and made up in 
Agilent hybridization buffer. Labelled cRNAs were then hybridized to RNG/MRC 
human pangenomic microarrays in an oven at 62°C for 16 hr. Microarrays were washed 
and scanned with a Genepix scanner (Axon Instruments, Molecular Devices Corporation 
Union City, CA). TIF images containing the data from each fluorescence channel were 
quantified with the Genepix pro 6.0 program (Axon Instruments). Normalization and 
statistical analysis was performed using the limma package available in Bioconductor 
(http://www.bioconductor.org).   11
 
Real-time reverse transcription-PCR 
Total RNA was isolated from cultured HeLa cells expressing the different constructs as 
indicated using TRIzol (Gibco BRL, Rockville, MD) according to the manufacturer's 
instructions. Specific primers for human atg12 (forward primer: 5-CGGGAACACCAAG 
TTTCACT-3; reverse primer: 5-TCTGGGGAGACATCCGTAAG-3); L32 (forward 
primer: 5-TGTCCTGAATGTGGTCACCTGA-3; reverse primer: 5-CTGCAGTCTCCTT 
GCACACCT-3); 18S (forward primer: 5-ACATCCAAGGAAGGCAGCAG-3; reverse 
primer: 5-TCGTCACTACCTCCCCGG-3); HPRT (forward primer: 5-GGACAGGACT 
GAACGTCTTGC-3; reverse primer: 5-CTTGAGCACACAGAGGGCTACA) and 
cyclophilin (forward primer: 5-GTCGACGGCGAGCCC-3; reverse primer: 5-
TCTTTGGGACCTTGTCTGCAA-3) were used. Real time PCR
TM was performed with 
Amplitaq Gold
TM polymerase in a Applied Biosystems 9700 thermocycler using SyBr 
Green
TM detection protocol as outlined by the manufacturer using the following PCR 
conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 
1 min. Atg12 mRNA was normalized against cyclophilin, L32, 18S and HPRT, allowing 
comparison of mRNA levels. 
Electron microscopy 
 
Cells were fixed in situ with 1.6% glutaraldehyde in 0.1 M phosphate buffer pH 7.5 at 
room temperature. Samples were rinsed carefully with same buffer then cells were post-
fixed with 1% osmium tetroxyde and 1% potassium ferricyanide to enhance the contrast 
of cytoplasmic membranes, rinsed with distilled water, dehydrated with ethanol and   12
finally embedded in Epon. Thin sections were contrasted with uranyl acetate and lead 
nitrate and observed with a Philips transmission electron microscope.  13
 
Supplemental Table 
  Act D 0.2 µM (6hrs)        Act D 0.2 µM (on)    
# 
Day 3 
post-treatment 
Day 10 
post-treatment #
Day 3 
post-treatment 
Day 10 
post-treatment 
1no cells  no cells  1cytC-GFP diffuse  no cells 
2no cells  no cells  2cytC-GFP diffuse  no cells 
3cytC-GFP diffuse  cytC-GFP punctate  3cytC-GFP diffuse  cytC-GFP punctate 
4cytC-GFP diffuse  cytC-GFP diffuse  4cytC-GFP punctate  no cells 
5cytC-GFP diffuse  cytC-GFP punctate  5cytC-GFP punctate  no cells 
6cytC-GFP diffuse  no cells  6cytC-GFP punctate  cytC-GFP punctate 
7cytC-GFP diffuse  no cells  7cytC-GFP diffuse  no cells 
8no cells  no cells  8cytC-GFP diffuse  no cells 
9cytC-GFP diffuse  cytC-GFP punctate  9cytC-GFP diffuse  cytC-GFP punctate 
10cytC-GFP diffuse  no cells  10cytC-GFP diffuse  no cells 
11no cells  no cells  11cytC-GFP diffuse  no cells 
12no cells  no cells  12cytC-GFP diffuse  no cells 
13cytC-GFP diffuse  cytC-GFP diffuse  13cytC-GFP punctate  no cells 
14cytC-GFP punctate  cytC-GFP diffuse  14cytC-GFP diffuse  cytC-GFP punctate 
15cytC-GFP punctate  cytC-GFP punctate  15cytC-GFP diffuse  no cells 
16cytC-GFP diffuse  no cells  16cytC-GFP punctate  no cells 
17cytC-GFP diffuse  no cells  17cytC-GFP diffuse  cytC-GFP punctate 
18cytC-GFP diffuse  no cells  18cytC-GFP diffuse  no cells 
19cytC-GFP diffuse  cytC-GFP punctate  19cytC-GFP diffuse  no cells 
20cytC-GFP diffuse  cytC-GFP punctate  20cytC-GFP diffuse  cytC-GFP punctate 
21cytC-GFP diffuse  no cells  21cytC-GFP diffuse  no cells 
22cytC-GFP diffuse  no cells  22cytC-GFP diffuse  no cells 
23cytC-GFP diffuse  no cells  23cytC-GFP diffuse  no cells 
24cytC-GFP diffuse  no cells  24no cells  no cells 
25cytC-GFP diffuse  cytC-GFP diffuse  25cytC-GFP diffuse  no cells 
26cytC-GFP diffuse  no cells  26cytC-GFP punctate  no cells 
27cytC-GFP diffuse  no cells  27cytC-GFP diffuse  no cells 
28cytC-GFP diffuse  cytC-GFP diffuse  28cytC-GFP diffuse  no cells 
29cytC-GFP diffuse  cytC-GFP punctate  29cytC-GFP diffuse  no cells 
30no cells  no cells  30no cells  no cells 
31cytC-GFP punctate  cytC-GFP punctate  31cytC-GFP diffuse  no cells 
32cytC-GFP diffuse  no cells  32cytC-GFP diffuse  no cells 
33cytC-GFP diffuse  no cells  33cytC-GFP diffuse  no cells 
34cytC-GFP punctate  no cells  34cytC-GFP diffuse  no cells 
35cytC-GFP punctate  cytC-GFP punctate  35cytC-GFP diffuse  no cells 
36cytC-GFP diffuse  cytC-GFP diffuse  36cytC-GFP punctate  no cells 
37cytC-GFP diffuse  no cells  37cytC-GFP diffuse  no cells   14
38cytC-GFP diffuse  no cells  38cytC-GFP diffuse  no cells 
39cytC-GFP diffuse  no cells  39cytC-GFP diffuse  cytC-GFP punctate 
40cytC-GFP diffuse  no cells  40cytC-GFP diffuse  no cells 
41cytC-GFP diffuse  cytC-GFP punctate  41cytC-GFP diffuse  no cells 
42cytC-GFP diffuse  no cells  42cytC-GFP diffuse  no cells 
43cytC-GFP diffuse  no cells  43cytC-GFP diffuse  no cells 
44cytC-GFP diffuse  cytC-GFP punctate  44cytC-GFP diffuse  no cells 
45no cells  no cells  45cytC-GFP diffuse  no cells 
46no cells  no cells  46cytC-GFP diffuse  no cells 
47cytC-GFP diffuse  no cells  47cytC-GFP diffuse  no cells 
48cytC-GFP diffuse  no cells  48cytC-GFP diffuse  no cells 
49cytC-GFP diffuse  no cells  49cytC-GFP diffuse  no cells 
50cytC-GFP diffuse  no cells  50cytC-GFP diffuse  no cells 
 
Table S1.  Approx. one HeLa cell (expressing GAPDH and cytochrome c-GFP) per 
microwell, treated with Act. D for indicated period (on, overnight) and cultured in 
caspase inhibitor (qVD-OPH, 20 µM).  Cells were assessed on day 0 (all cells showed 
punctate cytochrome c-GFP), and on days 3 and 10.  # indicates well number.  
 
 
 
 
 
 
 
 
 
 
 
 
 
   15
Supplemental Figures  
 
Figure S1. Strategy for identification of genes that promote resistance to caspase 
independent cell death.   16
 
 
 
 
 
 
 
Figure S2.  GAPDH preserves clonogenic growth in the presence of VD-fmk.  HeLa 
cells transduced with control or GAPDH encoding retrovirus were incubated for 6 hrs 
with Act D (0.2 µM), etoposide (5 µM), or STS (0.5 µM) as indicated, plus VD-fmk (50 
µM).  The caspase inhibitor was added 30 min before each apoptotic agent and replaced 
periodically at 24 hr intervals for 3 days. Viable cells were counted when indicated (up to 
12 days).    17
 
 
 
Figure S3. GAPDH promotes survival and proliferation during caspase independent 
cell death. Control or GAPDH-expressing HeLa cells were labelled with CFSE (5 µM)   18
for 10 min at 37
oC. After 3 washes cells were plated and treated the next day with Act D 
(0.2 µM) ± qVD-oph (20 µM). CFSE diffuses freely into cells and intracellular esterases 
cleave the acetate groups converting it to a fluorescent, membrane impermeant dye. 
During each round of cell division, the relative intensity of the dye is decreased by half.   
Cellular CFSE fluorescence was analyzed by flow cytometry from day 0 (day of 
treatment) up to day 10. 
 
 
 
 
 
Figure S4.  The protective effect of GAPDH is not due to disrupted p53 signaling.  
Apaf-1 null cells expressing E1A + H-Ras and E1A + GAPDH were exposed to UV 
(5 mJ/cm
2). 24 h later the expression of the p53-responsive gene p21
WAF1 was examined 
by western blot with anti-p21
WAF1 (clone SX118). Actin is shown as a loading control.   19
 
 
Figure S5. Mitochondrial cytochrome c recovery in GAPDH expressing cells.  (A) 
GAPDH-expressing HeLa cells transduced with cytochrome c-GFP were individually 
seeded in microwells on glass bottom dishes and incubated with Act D (0.2 µM) + qVD-  20
oph (20 µM) for 6 hrs.  Localization of cytochrome c-GFP was analyzed by confocal 
microscopy at 3 and 10 days after treatment.  (B) As in A.  The mitochondrial 
localization of the cytochrome c-GFP at day 12 was confirmed by staining with TMRE 
(50 nM, 20 min at 37
oC) and confocal analysis. Images from a single well are shown. 
 
 
 
Figure S6.  GAPDH expression delays the loss of ∆Ψm after treatment in the 
presence of caspase inhibitors.  Control or GAPDH expressing cells were treated for 6 
hrs with STS (0.5 µM) or etoposide (5 µM) ± qVD-oph (20 µM) and loss of ∆Ψm during   21
caspase independent cell death was measured by flow cytometry using the fluorescent 
dye TMRE. Quantitation represents an average of 3 independent experiments. 
 
 
 
 
 
Figure S7.  Enforced GAPDH expression increases ATP content. Intracellular ATP 
from total extracts of HeLa cells transduced with control or GAPDH-encoding retrovirus 
were analyzed by high-performance liquid chromatography as described in the 
Experimental procedures section. Values are means±S.D. of the results from two 
independent experiments. 
 
   22
 
 
 
Figure S8. Wild-type and GAPDH and GAPDH
152S/179F  mutant migrates to the 
nucleus upon apoptotic treatment. Representative images from confocal microscopy 
showing the cellular localization of the different mutants before or after 48 hrs treatment 
with etoposide (5 µM) in the presence of qVD-oph (20 µM).  
   23
 
 
Figure S9. None of the GAPDH mutants individually allow colony formation 
induced by E1A in Apaf-1
-/- MEFs. Early passage MEF from wt or Apaf-1
-/- mice were 
transduced with the indicated combination of vectors. Colonies were stained with 
methylene blue and assessed 12 days after transduction and selection.   24
 
 
Figure S10. Cells expressing both GAPDH∆2 and GAPDH
149S/176F mutants are 
capable of recovery from cytotoxic treatment in the presence of caspase inhibitors.  
(A) Levels of expression of GAPDH mutants in the stable lines were assessed by 
immunoblot with anti-V5. (B) HeLa cells expressing the wt or the mutants GAPDH∆2 
and GAPDH
149S/176F   illustrated in figure 5A were treated for 6 hrs with etoposide (5 µM) 
or STS (0.5 µM) ± qVD-oph (20 µM). Colonies were stained with methylene blue and 
assessed 12 days after treatment.   25
 
Figure S11.  Co-transduction with both GAPDH∆2 and GAPDH
149S/176F mutants 
allow growth of Apaf-1-deficient MEFs expressing E1A. Early passage MEFs from wt 
or Apaf-1
-/-
 mice were transduced with the indicated combination of vectors. Colonies 
were stained with methylene blue and assessed 12 days after transduction and selection. 
   26
 
 
Figure S12.  Redistribution of LC3-GFP in GAPDH-expressing cells. Twenty-four hrs 
after transient transfection with the LC3-GFP construct, cells were treated for 6 hrs with 
Act D (0.5 µM) + qVD-oph (20 µM).  LC3-GFP distribution was assessed by confocal 
microscopy 48 hrs after treatment. 
 
 
   27
 
 
 
 
 
 
 
Figure S13.  Pharmacologic inhibition of autophagy disrupts GAPDH-mediated 
protection from CICD.  Control or GAPDH-expressing HeLa cells were preincubated 
for 6 hrs with bafilomycin A1 (Baf A1; 0.1 µM) or 3-methyladenine (3-MA; 10 mM) and 
then treated with STS (1 µM) ± qVD-oph (20 µM) for 6 hrs. Colonies were stained with 
methylene blue and assessed 12 days after treatment.   28
 
 
Figure  S14. Atg5 knockdown inhibits autophagy. (A) HeLa cells were transfected with 
either pSuper, pSuper Atg 5I, II or III together with PMT2 HA-Atg5. Cells were lysed 
one day post-transfection and assayed for Atg 5 expression by immunoblot with anti-HA 
antibody. The membrane was re-probed with anti-actin antibody to confirm equal protein 
loading.  (B) HeLa cells stably transduced with GAPDH-V5 and either pSuper RV 
(vector), pSuper RV ATG 5II or pSuper RV ATG 5 III were analysed for Atg 5 
expression by real-time PCR. Shown are relative values following normalization against 
18s expression and are representative of three experiments ± S.D.  (C)  Cells in (B) were   29
transfected with LC3-GFP and cultured under suboptimum conditions to induce 
autophagy and LC3-GFP aggregation, assessed by fluorescent microscopy. 
 
 
Figure S15.  GAPDH but not GAPDH∆2 promotes loss of mitochondrial mass under 
conditions for CICD.  HeLa cells expressing GAPDH or GAPDH∆2 were treated and 
assessed as in the legend to Figure 6E.  Mitochondrial mass was assessed after 24 hrs. 
   30
 
 
 
Figure S16.  LC3 localizes to mitochondria in cells protected from CICD.   Cells were 
treated and assessed as in the legend to Figure 6G. 
 
   31
 
 
Figure S17.  Neither LC3B nor Atg5  protects cells from CICD. (A) Control or 
GAPDH∆2 expressing cells were transfected with constructs for expression of LC3B or 
Atg12 and 24 hrs later treated with STS (0.5 µM) + qVD-oph (20 µM) for 6 hrs. Colonies 
were stained with methylene blue and assessed 12 days after treatment. (B) Twenty-four 
hrs after transfection with constructs for expression of Atg5 or Atg12, cells were treated 
for 6 hrs with STS (0.5 µM) + qVD-oph (20 µM). Colonies were stained with methylene 
blue and assessed 12 days after treatment.    32
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